BioCryst Pharmaceuticals, Inc.
General ticker "BCRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.7B (TTM average)
BioCryst Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -3.7%.
Estimated limits based on current volatility of 4.5%: low 6.53$, high 7.14$
Factors to consider:
- Total employees count: 580 (+8.2%) as of 2024
- US accounted for 85.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Liquidity and credit risks, Regulatory and compliance, Supply chain disruptions, Cybersecurity threats, Geopolitical risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.92$, 12.60$]
- 2025-12-31 to 2026-12-31 estimated range: [5.74$, 12.33$]
Financial Metrics affecting the BCRX estimates:
- Negative: with PPE of -17.6 at the end of fiscal year the price was high
- Positive: -5.02 < Operating profit margin, % of -0.56
- Negative: Operating cash flow per share per price, % of -3.32 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 3.36 > -0.62
- Negative: Shareholder equity ratio, % of -97.05 <= 19.35
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: -0.18 < Industry inventory ratio change (median), % of 0
Short-term BCRX quotes
Long-term BCRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $270.83MM | $331.41MM | $450.71MM |
| Operating Expenses | $419.26MM | $435.12MM | $453.25MM |
| Operating Income | $-148.44MM | $-103.71MM | $-2.54MM |
| Non-Operating Income | $-95.95MM | $-122.52MM | $-84.41MM |
| Interest Expense | $99.09MM | $108.24MM | $98.52MM |
| R&D Expense | $253.30MM | $216.57MM | $174.64MM |
| Income(Loss) | $-244.38MM | $-226.23MM | $-86.95MM |
| Taxes | $2.73MM | $0.31MM | $1.93MM |
| Profit(Loss)* | $-247.12MM | $-226.54MM | $-88.88MM |
| Stockholders Equity | $-294.60MM | $-455.53MM | $-475.93MM |
| Assets | $550.00MM | $516.96MM | $490.42MM |
| Operating Cash Flow | $-161.85MM | $-95.14MM | $-52.02MM |
| Capital expenditure | $1.35MM | $2.17MM | $1.12MM |
| Investing Cash Flow | $-128.24MM | $-131.50MM | $52.59MM |
| Financing Cash Flow | $88.03MM | $32.48MM | $-5.76MM |
| Earnings Per Share** | $-1.33 | $-1.18 | $-0.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.